2-31529419-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3PP5
The NM_000348.4(SRD5A2):c.586G>A(p.Gly196Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000793 in 1,613,802 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00014 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000073 ( 1 hom. )
Consequence
SRD5A2
NM_000348.4 missense
NM_000348.4 missense
Scores
3
4
1
Clinical Significance
Conservation
PhyloP100: 7.84
Genes affected
SRD5A2 (HGNC:11285): (steroid 5 alpha-reductase 2) This gene encodes a microsomal protein expressed at high levels in androgen-sensitive tissues such as the prostate. The encoded protein is active at acidic pH and is sensitive to the 4-azasteroid inhibitor finasteride. Deficiencies in this gene can result in male pseudohermaphroditism, specifically pseudovaginal perineoscrotal hypospadias (PPSH). [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.836
PP5
Variant 2-31529419-C-T is Pathogenic according to our data. Variant chr2-31529419-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 3345.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=1, Uncertain_significance=1, Pathogenic=3}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SRD5A2 | NM_000348.4 | c.586G>A | p.Gly196Ser | missense_variant | 4/5 | ENST00000622030.2 | NP_000339.2 | |
SRD5A2 | XM_011533069.3 | c.364G>A | p.Gly122Ser | missense_variant | 4/5 | XP_011531371.1 | ||
SRD5A2 | XM_011533072.3 | c.331G>A | p.Gly111Ser | missense_variant | 6/7 | XP_011531374.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SRD5A2 | ENST00000622030.2 | c.586G>A | p.Gly196Ser | missense_variant | 4/5 | 1 | NM_000348.4 | ENSP00000477587 | P1 | |
ENST00000435713.1 | n.255+1719C>T | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.000151 AC: 23AN: 152158Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
23
AN:
152158
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000137 AC: 34AN: 248732Hom.: 0 AF XY: 0.000104 AC XY: 14AN XY: 134946
GnomAD3 exomes
AF:
AC:
34
AN:
248732
Hom.:
AF XY:
AC XY:
14
AN XY:
134946
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000725 AC: 106AN: 1461526Hom.: 1 Cov.: 31 AF XY: 0.0000674 AC XY: 49AN XY: 727038
GnomAD4 exome
AF:
AC:
106
AN:
1461526
Hom.:
Cov.:
31
AF XY:
AC XY:
49
AN XY:
727038
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000144 AC: 22AN: 152276Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74456
GnomAD4 genome
AF:
AC:
22
AN:
152276
Hom.:
Cov.:
32
AF XY:
AC XY:
9
AN XY:
74456
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
4
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
27
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:7Uncertain:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency Pathogenic:5Uncertain:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 1998 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 196 of the SRD5A2 protein (p.Gly196Ser). This variant is present in population databases (rs121434250, gnomAD 0.03%). This missense change has been observed in individual(s) with steroid 5-alpha-reductase deficiency (PMID: 18391525, 21147889, 21402750). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 3345). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SRD5A2 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects SRD5A2 function (PMID: 1522235). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital | Apr 19, 2011 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Jan 01, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 06, 2021 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with pseudovaginal perineoscrotal hypospadias (MIM#264600). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to serine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (37 heterozygotes, 0 homozygotes). (SP) 0502 - Missense variant with conflicting in silico predictions and very high conservation. (I) 0600 - Variant is located in the annotated steroid dehydrogenase domain (NCBI, PDB). (I) 0702 – Other missense variants comparable to the one identified in this case have strong previous evidence for pathogenicity. Residue 196 is considered to be a hotspot, with alternative changes to aspartic acid and arginine previously reported in individuals with pseudovaginal perineoscrotal hypospadias (MIM#264600) (ClinVar, PMIDs: 21402750, 28663096, 32346305). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. The variant has previously been reported, in either a homozygous or compound heterozygous state, in multiple individuals with pseudovaginal perineoscrotal hypospadias (MIM#264600) (ClinVar, HGMD, PMIDs: 1522235, 25248670, 28110336). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. The variant has been shown the result in decreased enzyme activity and a reduced affinity for NADPH (PMID: 1522235). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Biochemistry Laboratory, Health Services Laboratory | Nov 20, 2023 | ACMG:PS5 PM2 PM3 PP4 PP5 - |
SRD5A2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 20, 2024 | The SRD5A2 c.586G>A variant is predicted to result in the amino acid substitution p.Gly196Ser. This variant has been reported in the homozygous and compound heterozygous state in several individuals with steroid 5-alpha-reductase deficiency (see, for example, Thigpen et al. 1992. PubMed ID: 1522235; Table 3, Akcay et al. 2014. PubMed ID: 24737579; Abacı et al. 2018. PubMed ID: 30132287) and was found to segregate with a second pathogenic variant in a family with 5-alpha-reductase deficiency (Nordenskjöld and Ivarsson. 1998. PubMed ID: 9745434). In vitro functional studies using HEK 293 cells show reduced affinity to NADPH and an increase in optimal pH; however, it does not seem to have an effect on testosterone activity (Thigpen et al. 1992. PubMed ID: 1522235). This variant is predicted to alter splicing based on available splicing prediction programs (SpliceAI, Jaganathan et al. 2019. PubMed ID: 30661751). An alternate nucleotide change affecting the same amino acid (c.587G>T; p.Gly196Val) has been reported in individuals with 5-alpha-reductase deficiency (Cheng et al. 2019. PubMed ID: 31031332; Liu et al. 2022. PubMed ID: 35700942). This variant is reported in 0.029% of alleles in individuals of African descent in gnomAD. This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Jan 31, 2020 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Benign
FATHMM_MKL
Uncertain
D
MetaRNN
Pathogenic
D
PrimateAI
Uncertain
T
Sift4G
Uncertain
D
Vest4
MVP
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at